8-K: Foghorn Therapeutics Shifts Focus to Proprietary Pipeline and Lilly Collaboration, Discontinues Independent Development of FHD-286 in AML

Foghorn Therapeutics will discontinue independent development of FHD-286 in AML, prioritizing its proprietary pipeline and collaboration with Lilly.

Summary

• Foghorn Therapeutics has decided to stop the independent development of FHD-286 in combination with decitabine for relapsed or refractory acute myeloid leukemia (AML).
• This decision comes after a Phase 1 trial showed objective clinical responses, but the response rate did not meet the company's threshold for continued independent development.
• The company will now focus on its proprietary pipeline, including the selective CBP, EP300, and ARID1B programs, and its collaboration with Lilly, particularly the clinical development of FHD-909.
• Foghorn had $267.4 million in cash, cash equivalents, and marketable securities as of September 30, 2024, which is expected to fund operations into 2027.
• The company plans to present the results of the FHD-286 trial at a medical conference in 2025.

Sentiment

Score: 6

Explanation: The document contains both positive and negative elements. The discontinuation of FHD-286 is a setback, but the company's strong cash position, Lilly collaboration, and promising pipeline provide a positive outlook. The shift in focus is a strategic move that could benefit the company in the long term.

Positives

• Foghorn has a strong cash position of $267.4 million, providing a runway into 2027.
• The company has a strategic collaboration with Lilly, which includes significant upfront payments and potential milestones.
• Foghorn is advancing multiple programs targeting chromatin biology, a promising area for cancer therapeutics.
• The company's pipeline includes several first-in-class precision therapeutics with potential for broad application in oncology.
• Pre-clinical data for the CBP degrader shows no thrombocytopenia and spares megakaryocytes in vivo.
• Pre-clinical studies indicate long-acting injectable formulations of the CBP degrader could enable at least once every 2 weeks dosing.
• The company has identified selective ARID1B binders with improved binding affinity.

Negatives

• The independent development of FHD-286 in combination with decitabine for AML has been discontinued due to insufficient efficacy.
• The company will need to seek partnerships or investigator-sponsored trials to further advance FHD-286.
• The company is still in the early stages of development for many of its programs, with several in pre-clinical stages.

Risks

• The company's forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The company may face challenges in manufacturing and research, relying on CDMOs and CROs.
• The company may need additional financing in the future.
• There are risks associated with competition and the company's ability to protect its intellectual property.
• The company's business is subject to substantial risks and uncertainties, including macroeconomic and geopolitical circumstances.

Future Outlook

Foghorn Therapeutics will prioritize its proprietary pipeline and Lilly collaboration programs, including the clinical development of FHD-909, and expects to advance multiple high-value assets into the clinic between 2025 and 2027. The company anticipates several near-term value inflection points through 2026, including IND filings and clinical data readouts.

Management Comments

• Adrian Gottschalk, President and Chief Executive Officer of Foghorn, stated that the company will prioritize investment into its proprietary pipeline and Lilly collaboration, including the clinical development of FHD-909.
• He also mentioned that the company's pipeline represents significant opportunities in oncology with the potential for therapeutic expansion.

Industry Context

This announcement reflects a strategic shift in focus for Foghorn, prioritizing its most promising programs and partnerships. The decision to discontinue independent development of FHD-286 highlights the challenges in drug development and the need to allocate resources effectively. The company's focus on chromatin biology aligns with a growing interest in this area as a target for cancer therapeutics.

Comparison to Industry Standards

• Foghorn's approach to targeting chromatin biology is unique, as many companies focus on more traditional targets.
• The company's collaboration with Lilly is a significant validation of its technology and approach, as Lilly is a major player in the pharmaceutical industry.
• The 50/50 U.S. economic split on two programs with Lilly is a favorable deal structure for Foghorn.
• The company's focus on protein degraders is in line with a growing trend in the industry, as these molecules offer the potential to target previously undruggable proteins.
• The company's pre-clinical data for its CBP and EP300 degraders is promising, as these targets have been challenging to drug due to selectivity issues.
• The company's identification of selective ARID1B binders is a significant step forward, as this target has been difficult to engage.

Stakeholder Impact

• Shareholders may be concerned about the discontinuation of FHD-286, but the focus on other programs and the Lilly collaboration could be seen as positive.
• Employees may be affected by the shift in priorities, but the company's strong financial position should provide stability.
• Patients with AML may be disappointed by the discontinuation of FHD-286, but the company's other programs may offer new treatment options in the future.
• The company's collaboration with Lilly could benefit both companies and their stakeholders.

Next Steps

• Foghorn will prioritize its proprietary pipeline and Lilly collaboration programs.
• The company will seek partnerships or investigator-sponsored trials to advance FHD-286.
• Foghorn will report the results of the FHD-286 trial at a medical conference in 2025.
• The company will continue to advance its pre-clinical assets towards IND filings.
• Foghorn will continue the Phase 1 dose escalation trial of FHD-909.

Key Dates

Keywords

Foghorn Therapeutics, FHD-909, SMARCA2, AML, chromatin biology, protein degrader, Lilly collaboration, oncology, precision therapeutics, CBP, EP300, ARID1B, cancer, clinical trial